Nerve Entrapment Syndrome Therapeutics Market 2023 to 2033

Q: What is the Growth Potential of the Market?

The growth potential of the market is 6.81% through 2033. Read Report

Request Methodology

Nerve Entrapment Syndrome Therapeutics Market Snapshot (2023 to 2033)

The global nerve entrapment syndrome therapeutics is slated to reach a valuation of US$ 4.16 billion in 2023. According to Future Market Insights, the market is expected to grow at a 6.81% CAGR until 2033, valued at US$ 8.04 billion.

As per the reports of Future Market Insights, around 60–70% of people suffering from diabetes are projected to have diabetic neuropathy. As per the records of the International Diabetes Federation (IDF), in 2019, around 463 million adults (20-79 years) were living with diabetes, and by 2045 this will rise to 700 million. This rising pool of diabetic patients is leading to a surge in incidences of neuropathic pain worldwide, which will ultimately boost the growth of neuropathic pain management.

There are various side effects of medications that are estimated to limit the growth of the market. Wide use of opioids and steroids may lead to several complications such as heart attack, kidney failure, and lung damage. This hampers the market growth.

The increasing launch of drugs for treating neural pain led to the growth of the market. For instance, in March 2020, Senzer Pharmaceuticals secured the Investigational New Drug application and data package for its ongoing FDA registration program from its former U.S. strategic partner for receiving approval for its cannabinoid respiratory device for treating the side effects induced by anti-cancer treatments, especially nausea, vomiting, and neuropathic pain.

Attributes	Details
Projected Forecast Value (2023)	US$ 4.16 billion
Projected Forecast Value (2033)	US$ 8.04 billion
Growth rate	6.81% CAGR
Forecast period	2023 to 2033

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Nerve Entrapment Syndrome Therapeutics Market Historical Period 2018 To 2022 Demand Analysis Vs. Forecast 2023

The global nerve entrapment syndrome therapeutics market grew at a CAGR of 5.86% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.

The presentation can certainly vary, given multiple areas of possible entrapment. Symptoms usually develop very slowly. The duration of symptoms often averages multiple years before a definitive diagnosis is made. As mentioned previously, symptoms of this type of nerve entrapment include pain, sensory and motor changes, paresthesias, and/or paralysis. Physical exam and/or history often reveal symptoms limited to the dorso-radial aspect of the distal forearm and hand.

Findings of decreased sensation over the dorso-radial aspect of the forearm or hand help establish the diagnosis. A positive Tinel sign along the radial aspect of the mid-forearm is suggestive of this process. Wrist flexion, ulnar deviation, and pronation place strain on the nerve and will often reproduce or exacerbate symptoms. Resisting the extension of the middle finger with the elbow extended is another sign of nerve entrapment. This sign is often used to aid in the diagnosis of lateral epicondylitis, but it is also often positive in cases of radial nerve entrapment.

The latest research study states that the acute management of radial nerve entrapment is surgical, less severe cases can employ conservative management. However, once the surgery is completed, the patient needs to be followed by an interprofessional team that includes a neurologist, hand surgeon, specialty-trained nurses, and physical and occupational therapists.

After the healing is complete, most patients require extensive rehabilitation to recover motor and sensory function. In addition, the patient must wear protective splints to protect the hand. Orthopedic nurses monitor patients and provide education. Recovery often takes months, and compliance with the exercise program is key.

Prominent Growth Drivers Influencing Nerve Entrapment Syndrome Therapeutics Market

Increased Clinical Research Activities

Key market players are focused on conducting clinical trials to expand their market growth. For instance, in February 2020, NoNO Inc., which is a privately-held biotechnology company, stated that nerine tide, without prior administration of alteplase, demonstrated medically important improvements in patients suffering from acute ischemic stroke, in a multicenter, randomized, study. Additionally, in March 2020, several scientists from Heidelberg University, Germany, stated evaluation of the phytochemical composition and the possible prophylactic effects of an aqueous ethanol extract of Haematoxylon campechianum flowers on peripheral neuropathic pain in a chronic constriction injury rat model.

High incidence of nerve injuries

The increasing prevalence of neurological disorders and the high volume of cases of nerve injuries place a great demand for nerve repair and regeneration products. The geriatric population across the globe is rising and the vast population base and the massive prevalence and incidence of nerve-related diseases among them drive the growth of the market. The market players and researchers are more focused on advancing neurostimulation and neuromodulation technologies such as next-generation neurostimulation devices, collaborations among the companies to launch advanced products and the incoming latest technologies are thus pushing the growth of the market.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What Could Possibly Hinder the market growth of the Nerve Entrapment Syndrome Therapeutics Market?

Complications For Neural Pain Treatment

This neural pain treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.

To gain more info on the neural pain treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

What Could Possibly be the key opportunity for Nerve Entrapment Syndrome Therapeutics Market?

Increasing Drug Approvals by Several Authorized Organizations

The wide approval of the drugs by various regulatory authorities of the different regions contributes to the market's growth. For instance, in July 2020, Grünenthal and its U.S. subsidiary, Averitas Pharma, Inc., received USA FDA approval for QUTENZA 8% patch for the treatment of neuropathic pain related to diabetic peripheral neuropathy (DPN) of the feet in adults.

It is a topical, non-systemic, non-opioid pain treatment that is delivered in the form of a patch and is the first and only treatment of its kind to deliver prescription-strength capsaicin directly into the skin. Such kinds of approvals of the different routes of administration of drugs are projected to boost the growth of the market.

Region-wise Analysis

What Is the Outlook of The North American Nerve Entrapment Syndrome Therapeutics Market?

Availability of physicians and favorable reimbursement policies

North America is expecting positive growth for the nerve entrapment syndrome therapeutics market throughout the forecasted period because of the presence of a large number of pain specialist physicians and the increasing number of approvals from the FDA.

The U.S. held approximately 89.5% share in the global nerve entrapment syndrome therapeutics market whereas sales in the U.S. is expected to grow at a CAGR of 13.3%.

Growth in the market is also underpinned due to the presence of several health insurance companies, where these companies incorporate government programs to provide insurance coverage for standard procedures in nerve repair and regeneration.

What Can Be Expected from the East Asian Market for Nerve Entrapment Syndrome Therapeutics Market?

China contributes 2/5th of sales in the global nerve repair

According to the reports of FMI, China is said to hold a demand share of 37.6% in the East Asia nerve repair market. With the rise in awareness regarding neurological disorders and the increase in government initiatives, China is expected to witness favorable growth in the forecast period which is mostly due to the presence of numerous biomaterials and mobility device manufacturing companies.

Category-wise Insights

Which Type of End-user in Nerve Entrapment Syndrome Therapeutics Market is Most Prevalent?

Hospitals to Generate 3/5 of Revenue in Nerve Entrapment Syndrome Therapeutics Market

The hospital segment holds the highest market share at about 58.6%. The availability of advanced medical equipment for comprehensive patient care in hospitals is the key factor that propels the growth in this segment. Also with contracts, the multiple distribution channels, hospitals can provide services with subsidized costs for equipment.

Antidepressants are said to hold a dominant share

Antidepressants are said to hold dominance in the market share. Although, the most popular theory is that antidepressants exert their effects on serotonin and norepinephrine, particularly along the descending spinal pain pathways. Antidepressants may also exert adjunctive therapeutic influences through histamine receptors as well as the modulation of sodium channels.

Start-up Scenario

Theranica- Developer of chip-based wearable patches for neuromodulation therapy. It uses wireless technology to develop a proprietary wearable patch that has a proprietary chip that can deliver electrical pulses to neuromodulate the sensory nerves under the skin. Its patch can be controlled by a smartphone app and can be used for personalized, portable, and affordable care. It is applicable for the acute treatment of migraine headaches.
Biowave Corporation develops and markets neuromodulation pain therapy devices aiming to aid physicians, physical therapists, and athletic trainers manage their patients' or athletes’ pain and reduce the use of drugs.
The BiowavePRO and Homewave neuromodulation devices deliver a therapeutic electrical pulse into deep tissue in the body blocking the transmission of pain. The devices have received marketing clearance from the FDA (Sep 2015) and are indicated to treat musculoskeletal pain that is chronic, acute, or post-operative in nature and located in the low back, cervical spine, shoulder, elbow, wrist, hand, hip, knee, ankle, and foot.
ShiraTronics (a spinout from NuXcel) is a developer of neuromodulation devices for treating migraines. The company claims that the implant uses neuromodulation technologies to treat migraine and other chronic diseases. Some of the partners are AMZAK, APERTURE, and LivaNova.

How Competitive Is the Market for Nerve Entrapment Syndrome Therapeutics Market?

Some of the prominent players in the global market for Nerve Entrapment Syndrome Therapeutics Market treatment are

Abbott Laboratories
Assertio Therapeutics Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Aurobindo Pharma Ltd.
Baxter International Inc.
Biogen Inc.
Bristol Myers Squibb Co.
Dr. Reddy’s Laboratories Ltd
Eli Lilly and Co.
Endo International Plc

Some of the important developments of the key players in the market are

In 2022, Daiichi Sankyo Company, Limited received approval in Japan to change the indication of the analgesic Tarlige Tablets (mirogabalin besilate) from peripheral neuropathic pain to neuropathic pain.
In 2022, Integra LifeSciences Holding Corporation announced the launch of NeuraGen 3D Nerve Guide Matrix, a resorbable implant for the repair of peripheral nerve discontinuities.

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 6.81% from 2023 to 2033
Market value in 2023	US$ 4.16 Billion
Market value in 2033	US$ 8.04 billion
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	USD billion for Value and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Region Treatment End-user
Regions Covered	North America Latin America Europe South Asia East Asia Oceania Middle East & Africa
Key Countries Profiled	United States Canada Brazil Mexico Germany United Kingdom France Spain Italy India Malaysia Singapore Thailand China Japan South Korea Australia New Zealand GCC countries South Africa Israel
Key Companies Profiled	Abbott Laboratories Assertio Therapeutics Inc. Astellas Pharma Inc. AstraZeneca Plc Aurobindo Pharma Ltd. Baxter International Inc. Biogen Inc. Bristol Myers Squibb Co. Dr. Reddy’s Laboratories Ltd Eli Lilly and Co. Endo International Plc
Customisation Scope	Available on Request

Key Segments Profiled in the Respiratory Distress Syndrome Management Market Report

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Treatment:

Pharmacological Therapies
- Pain Relievers
- Anti-seizure Medications
- Antidepressants
Non-pharmacological Therapies
- Transcutaneous Electrical Nerve Stimulation
- Plasma Exchange
- Others

End User:

Hospitals
Clinics
Research centers

Frequently Asked Questions

What is the Valuation of Nerve Entrapment Syndrome Therapeutics Market?

The nerve entrapment syndrome therapeutics market is estimated to secure a valuation of US$ 4.16 billion in 2023.

What is the Projected Size of the Market by 2033?

The global market size is expected to reach US$ 8.04 billion by 2033.

What is the Growth Potential of the Market?

The growth potential of the market is 6.81% through 2033.

What is the best treatment for nerve entrapment?

Antidepressants serve as the suitable treatment for nerve entrapment syndrome.

Which End User Registered Significant Demand for Nerve Entrapment Syndrome Therapeutics?

Hospitals segment accounts for 3/5th of the overall market revenue.

Table of Content

1. Executive Summary | Nerve Entrapment Syndrome Therapeutics Market

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

5.3.1. Pharmacological Therapies

5.3.1.1. Pain Relievers

5.3.1.2. Anti-seizure Medications

5.3.1.3. Antidepressants

5.3.2. Non-pharmacological Therapies

5.3.2.1. Transcutaneous Electrical Nerve Stimulation

5.3.2.2. Plasma Exchange

5.3.2.3. Others

5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

6.3.1. Hospitals

6.3.2. Clinics

6.3.3. Research Centres

6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

7.1. Introduction

7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

7.3.1. North America

7.3.2. Latin America

7.3.3. Europe

7.3.4. South Asia

7.3.5. East Asia

7.3.6. Oceania

7.3.7. MEA

7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

8.2.1. By Country

8.2.1.1. USA

8.2.1.2. Canada

8.2.2. By Treatment

8.2.3. By End User

8.3. Market Attractiveness Analysis

8.3.1. By Country

8.3.2. By Treatment

8.3.3. By End User

8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

9.2.1. By Country

9.2.1.1. Brazil

9.2.1.2. Mexico

9.2.1.3. Rest of Latin America

9.2.2. By Treatment

9.2.3. By End User

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Treatment

9.3.3. By End User

9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

10.2.1. By Country

10.2.1.1. Germany

10.2.1.2. United kingdom

10.2.1.3. France

10.2.1.4. Spain

10.2.1.5. Italy

10.2.1.6. Rest of Europe

10.2.2. By Treatment

10.2.3. By End User

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Treatment

10.3.3. By End User

10.4. Key Takeaways

11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

11.2.1. By Country

11.2.1.1. India

11.2.1.2. Malaysia

11.2.1.3. Singapore

11.2.1.4. Thailand

11.2.1.5. Rest of South Asia

11.2.2. By Treatment

11.2.3. By End User

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Treatment

11.3.3. By End User

11.4. Key Takeaways

12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

12.2.1. By Country

12.2.1.1. China

12.2.1.2. Japan

12.2.1.3. South Korea

12.2.2. By Treatment

12.2.3. By End User

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Treatment

12.3.3. By End User

12.4. Key Takeaways

13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

13.2.1. By Country

13.2.1.1. Australia

13.2.1.2. New Zealand

13.2.2. By Treatment

13.2.3. By End User

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Treatment

13.3.3. By End User

13.4. Key Takeaways

14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

14.2.1. By Country

14.2.1.1. GCC Countries

14.2.1.2. South Africa

14.2.1.3. Israel

14.2.1.4. Rest of MEA

14.2.2. By Treatment

14.2.3. By End User

14.3. Market Attractiveness Analysis

14.3.1. By Country

14.3.2. By Treatment

14.3.3. By End User

14.4. Key Takeaways

15. Key Countries Market Analysis

15.1. USA

15.1.1. Pricing Analysis

15.1.2. Market Share Analysis, 2022

15.1.2.1. By Treatment

15.1.2.2. By End User

15.2. Canada

15.2.1. Pricing Analysis

15.2.2. Market Share Analysis, 2022

15.2.2.1. By Treatment

15.2.2.2. By End User

15.3. Brazil

15.3.1. Pricing Analysis

15.3.2. Market Share Analysis, 2022

15.3.2.1. By Treatment

15.3.2.2. By End User

15.4. Mexico

15.4.1. Pricing Analysis

15.4.2. Market Share Analysis, 2022

15.4.2.1. By Treatment

15.4.2.2. By End User

15.5. Germany

15.5.1. Pricing Analysis

15.5.2. Market Share Analysis, 2022

15.5.2.1. By Treatment

15.5.2.2. By End User

15.6. United kingdom

15.6.1. Pricing Analysis

15.6.2. Market Share Analysis, 2022

15.6.2.1. By Treatment

15.6.2.2. By End User

15.7. France

15.7.1. Pricing Analysis

15.7.2. Market Share Analysis, 2022

15.7.2.1. By Treatment

15.7.2.2. By End User

15.8. Spain

15.8.1. Pricing Analysis

15.8.2. Market Share Analysis, 2022

15.8.2.1. By Treatment

15.8.2.2. By End User

15.9. Italy

15.9.1. Pricing Analysis

15.9.2. Market Share Analysis, 2022

15.9.2.1. By Treatment

15.9.2.2. By End User

15.10. India

15.10.1. Pricing Analysis

15.10.2. Market Share Analysis, 2022

15.10.2.1. By Treatment

15.10.2.2. By End User

15.11. Malaysia

15.11.1. Pricing Analysis

15.11.2. Market Share Analysis, 2022

15.11.2.1. By Treatment

15.11.2.2. By End User

15.12. Singapore

15.12.1. Pricing Analysis

15.12.2. Market Share Analysis, 2022

15.12.2.1. By Treatment

15.12.2.2. By End User

15.13. Thailand

15.13.1. Pricing Analysis

15.13.2. Market Share Analysis, 2022

15.13.2.1. By Treatment

15.13.2.2. By End User

15.14. China

15.14.1. Pricing Analysis

15.14.2. Market Share Analysis, 2022

15.14.2.1. By Treatment

15.14.2.2. By End User

15.15. Japan

15.15.1. Pricing Analysis

15.15.2. Market Share Analysis, 2022

15.15.2.1. By Treatment

15.15.2.2. By End User

15.16. South Korea

15.16.1. Pricing Analysis

15.16.2. Market Share Analysis, 2022

15.16.2.1. By Treatment

15.16.2.2. By End User

15.17. Australia

15.17.1. Pricing Analysis

15.17.2. Market Share Analysis, 2022

15.17.2.1. By Treatment

15.17.2.2. By End User

15.18. New Zealand

15.18.1. Pricing Analysis

15.18.2. Market Share Analysis, 2022

15.18.2.1. By Treatment

15.18.2.2. By End User

15.19. GCC Countries

15.19.1. Pricing Analysis

15.19.2. Market Share Analysis, 2022

15.19.2.1. By Treatment

15.19.2.2. By End User

15.20. South Africa

15.20.1. Pricing Analysis

15.20.2. Market Share Analysis, 2022

15.20.2.1. By Treatment

15.20.2.2. By End User

15.21. Israel

15.21.1. Pricing Analysis

15.21.2. Market Share Analysis, 2022

15.21.2.1. By Treatment

15.21.2.2. By End User

16. Market Structure Analysis

16.1. Competition Dashboard

16.2. Competition Benchmarking

16.3. Market Share Analysis of Top Players

16.3.1. By Regional

16.3.2. By Treatment

16.3.3. By End User

17. Competition Analysis

17.1. Competition Deep Dive

17.1.1. Abbott Laboratories

17.1.1.1. Overview

17.1.1.2. Product Portfolio

17.1.1.3. Profitability by Market Segments

17.1.1.4. Sales Footprint

17.1.1.5. Strategy Overview

17.1.1.5.1. Marketing Strategy

17.1.2. Assertio Therapeutics Inc.

17.1.2.1. Overview

17.1.2.2. Product Portfolio

17.1.2.3. Profitability by Market Segments

17.1.2.4. Sales Footprint

17.1.2.5. Strategy Overview

17.1.2.5.1. Marketing Strategy

17.1.3. Astellas Pharma Inc.

17.1.3.1. Overview

17.1.3.2. Product Portfolio

17.1.3.3. Profitability by Market Segments

17.1.3.4. Sales Footprint

17.1.3.5. Strategy Overview

17.1.3.5.1. Marketing Strategy

17.1.4. AstraZeneca Plc

17.1.4.1. Overview

17.1.4.2. Product Portfolio

17.1.4.3. Profitability by Market Segments

17.1.4.4. Sales Footprint

17.1.4.5. Strategy Overview

17.1.4.5.1. Marketing Strategy

17.1.5. Aurobindo Pharma Ltd.

17.1.5.1. Overview

17.1.5.2. Product Portfolio

17.1.5.3. Profitability by Market Segments

17.1.5.4. Sales Footprint

17.1.5.5. Strategy Overview

17.1.5.5.1. Marketing Strategy

17.1.6. Baxter International Inc.

17.1.6.1. Overview

17.1.6.2. Product Portfolio

17.1.6.3. Profitability by Market Segments

17.1.6.4. Sales Footprint

17.1.6.5. Strategy Overview

17.1.6.5.1. Marketing Strategy

17.1.7. Biogen Inc.

17.1.7.1. Overview

17.1.7.2. Product Portfolio

17.1.7.3. Profitability by Market Segments

17.1.7.4. Sales Footprint

17.1.7.5. Strategy Overview

17.1.7.5.1. Marketing Strategy

17.1.8. Bristol Myers Squibb Co.

17.1.8.1. Overview

17.1.8.2. Product Portfolio

17.1.8.3. Profitability by Market Segments

17.1.8.4. Sales Footprint

17.1.8.5. Strategy Overview

17.1.8.5.1. Marketing Strategy

17.1.9. Dr Reddy’s Laboratories Ltd

17.1.9.1. Overview

17.1.9.2. Product Portfolio

17.1.9.3. Profitability by Market Segments

17.1.9.4. Sales Footprint

17.1.9.5. Strategy Overview

17.1.9.5.1. Marketing Strategy

17.1.10. Eli Lilly and Co.

17.1.10.1. Overview

17.1.10.2. Product Portfolio

17.1.10.3. Profitability by Market Segments

17.1.10.4. Sales Footprint

17.1.10.5. Strategy Overview

17.1.10.5.1. Marketing Strategy

17.1.11. Endo International Plc

17.1.11.1. Overview

17.1.11.2. Product Portfolio

17.1.11.3. Profitability by Market Segments

17.1.11.4. Sales Footprint

17.1.11.5. Strategy Overview

17.1.11.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 15: South Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 18: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 20: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 21: Oceania Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 22: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 23: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 24: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by End User, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 14: Global Market Attractiveness by End User, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by End User, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 29: North America Market Attractiveness by End User, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by End User, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 44: Latin America Market Attractiveness by End User, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 59: Europe Market Attractiveness by End User, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 62: South Asia Market Value (US$ Million) by End User, 2023 to 2033

Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 68: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 70: South Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 71: South Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 72: South Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 73: South Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 74: South Asia Market Attractiveness by End User, 2023 to 2033

Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 76: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 77: East Asia Market Value (US$ Million) by End User, 2023 to 2033

Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 83: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 85: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 86: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 87: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 88: East Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 89: East Asia Market Attractiveness by End User, 2023 to 2033

Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 91: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 92: Oceania Market Value (US$ Million) by End User, 2023 to 2033

Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 97: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 98: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 100: Oceania Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 101: Oceania Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 102: Oceania Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 103: Oceania Market Attractiveness by Treatment, 2023 to 2033

Figure 104: Oceania Market Attractiveness by End User, 2023 to 2033

Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 106: MEA Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 107: MEA Market Value (US$ Million) by End User, 2023 to 2033

Figure 108: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 109: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 110: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 111: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 112: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 113: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 114: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 115: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 116: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 117: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 118: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 119: MEA Market Attractiveness by End User, 2023 to 2033

Figure 120: MEA Market Attractiveness by Country, 2023 to 2033

April 2023

REP-GB-17033

303 pages

Healthcare

Sabyasachi Ghosh

Book Now

Clients

Customize This Research

Quick Contact

Chat on Whatsapp + 44 (0) 20 3287 4268 + 44 (0) 20 8123 9659 + 1 347 918 3531 Contact By Email

- Trust FMI -

- Member of -

Greater New York Chamber of Commerce

- Awarded by -

BRONZE STEVIE® Award

20th annual IBAs

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

- Recognized by -

Nerve Entrapment Syndrome Therapeutics Market

Nerve Entrapment Syndrome Therapeutics Market by Treatment, End-user & Region | Forecast From 2023 to 2033